Infinity Stock Executives

INFI -  USA Stock  

USD 2.64  0.05  1.86%

Infinity Pharmaceuti employes about 23 people. The company is managed by 19 executives with total tenure of roughly 134 years, averaging almost 7.0 years of service per executive having 1.21 employees per reported executive. Examination of Infinity Pharmaceuti management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Infinity Pharmaceuti future performance.
Please see Risk vs Return Analysis.

Infinity Insiders 

 
Refresh
  Adelene Perkins  Chairman
Chairman of The Board, CEO and Pres
  Joseph Pearlberg  President
Vice President - Clinical Development
  Melissa Hackel  President
Vice President - Finance

Infinity Pharmaceuti Return on Sales

(22.72)Share

Infinity Pharmaceuti Management Team Effectiveness

Infinity Pharmaceuti has return on total asset (ROA) of (34.64) % which means that it has lost $34.64 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (285.39) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuti management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Equity is estimated to increase to 3.44, while Return on Investment is projected to decrease to (179.10) . Infinity Pharmaceuti Assets Non Current are most likely to decrease significantly in the upcoming years. The last year's value of Assets Non Current was reported at 3.3 Million. The current Revenue to Assets is estimated to increase to 0.0449, while Return on Average Assets are projected to decrease to (0.86) .

Infinity Pharmaceuti Quarterly Total Assets

102.6 MillionShare
The current Issuance Purchase of Equity Shares is estimated to increase to about 8.1 M, while Weighted Average Shares is projected to decrease to roughly 58 M.

Infinity Pharmaceuti Workforce Comparison

Infinity Pharmaceuti is currently regarded as number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 36.0. Infinity Pharmaceuti totals roughly 23.0 in number of employees claiming about 64% of stocks in Biotechnology industry.

Infinity Pharmaceuti Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Infinity Pharmaceuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Infinity Pharmaceuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Infinity Pharmaceuti insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Infinity Pharmaceuti Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Infinity Pharmaceuti Price Series Division is a division of Infinity Pharmaceuti price series and its benchmark/peer. View also all equity analysis or get more info about price series division math operators indicator.

Infinity Pharmaceuti Notable Stakeholders

An Infinity Pharmaceuti stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Infinity Pharmaceuti often face trade-offs trying to please all of them. Infinity Pharmaceuti's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Infinity Pharmaceuti's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Adelene Perkins - Chairman of The Board, CEO and PresProfile
Joseph Pearlberg - Vice President - Clinical DevelopmentProfile
Melissa Hackel - Vice President - FinanceProfile
William Bertrand - Executive Vice President General CounselProfile
Lawrence Bloch - CFO, Executive Vice President Chief Business OfficerProfile
Julian Adams - President of RandDProfile
Sujay Kango - Executive Vice President Chief Commercial OfficerProfile
Vito Palombella - Chief Scientific Officer and Executive VPProfile
Jeffrey Berkowitz - Independent DirectorProfile
Norman Selby - Lead Outside Independent DirectorProfile
Jose Baselga - Independent DirectorProfile
Michael Venuti - Independent DirectorProfile
Michael Kauffman - Independent DirectorProfile
Eric Lander - Independent DirectorProfile
David Beier - Independent DirectorProfile
Anthony Evnin - Independent DirectorProfile
Gwendolyn Fyfe - Independent DirectorProfile
Ian Smith - Independent DirectorProfile
Samuel Agresta - Chief Medical OfficerProfile

About Infinity Pharmaceuti Management Performance

The success or failure of an entity such as Infinity Pharmaceuti often depends on how effective the management is. Infinity Pharmaceuti management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Infinity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Infinity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Investment(174.51) (179.10) 
Return on Average Assets(0.84) (0.86) 
Return on Average Equity 3.19  3.44 
Return on Invested Capital(2.86) (2.94) 
Return on Sales(22.13) (22.72) 
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 23 people.
The data published in Infinity Pharmaceuti's official financial statements usually reflect Infinity Pharmaceuti's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Infinity Pharmaceuti. For example, before you start analyzing numbers published by Infinity accountants, it's critical to develop an understanding of what Infinity Pharmaceuti's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Infinity Pharmaceuti's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Infinity Pharmaceuti's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Infinity Pharmaceuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Infinity Pharmaceuti. Please utilize our Beneish M Score to check the likelihood of Infinity Pharmaceuti's management to manipulate its earnings.

Infinity Pharmaceuti Workforce Analysis

Traditionally, organizations such as Infinity Pharmaceuti use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Infinity Pharmaceuti within its industry.

Infinity Pharmaceuti Manpower Efficiency

Return on Infinity Pharmaceuti Manpower

Revenue Per Employee76.5 K
Revenue Per Executive100.5 K
Net Loss Per Employee1.9 M
Net Loss Per Executive2.3 M
Working Capital Per Employee8 M
Working Capital Per Executive9.7 M
Today, most investors in Infinity Pharmaceuti Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Infinity Pharmaceuti's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Infinity Pharmaceuti per employee as a starting point in their analysis.

Per Employee

Infinity Pharmaceuti Per Employee Growth Over Time

Net Income Per Employee

(1.89 Million)Share
Infinity Pharmaceuti Net Income Per Employee is most likely to decrease significantly in the upcoming years. The last year's value of Net Income Per Employee was reported at (1.76 Million)

Revenue Per Employee

76,496.45Share
Infinity Pharmaceuti Revenue Per Employee is most likely to decrease significantly in the upcoming years. The last year's value of Revenue Per Employee was reported at 74,535
Please see Risk vs Return Analysis. Note that the Infinity Pharmaceuti information on this page should be used as a complementary analysis to other Infinity Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Infinity Stock analysis

When running Infinity Pharmaceuti price analysis, check to measure Infinity Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuti is operating at the current time. Most of Infinity Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Infinity Pharmaceuti's price. Additionally, you may evaluate how the addition of Infinity Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
The market value of Infinity Pharmaceuti is measured differently than its book value, which is the value of Infinity that is recorded on the company's balance sheet. Investors also form their own opinion of Infinity Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Infinity Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Infinity Pharmaceuti's market value can be influenced by many factors that don't directly affect Infinity Pharmaceuti underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Infinity Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Infinity Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Infinity Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.